Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.35
+0.05 (0.44%)
At close: Mar 9, 2026, 4:00 PM EDT
11.39
+0.04 (0.35%)
After-hours: Mar 9, 2026, 5:26 PM EDT
Keros Therapeutics Revenue
In the year 2025, Keros Therapeutics had annual revenue of $244.06M with 6,774.96% growth. Keros Therapeutics had revenue of $385.00K in the quarter ending December 31, 2025, a decrease of -87.34%.
Revenue (ttm)
$244.06M
Revenue Growth
+6,774.96%
P/S Ratio
0.92
Revenue / Employee
$3,128,987
Employees
78
Market Cap
223.79M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 61.84M |
| Editas Medicine | 40.52M |
| Voyager Therapeutics | 40.37M |
| MediWound | 16.96M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 1.57M |
KROS News
- 15 hours ago - Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - GlobeNewsWire
- 15 hours ago - Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - GlobeNewsWire
- 5 days ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 11 days ago - Keros Therapeutics Appoints Charles Newton to its Board of Directors - GlobeNewsWire
- 19 days ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces Final Results of Tender Offer - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces Preliminary Results of Tender Offer - GlobeNewsWire
- 4 months ago - Keros Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire